Skip to content

Gastric pH and Anthocyanin Absorption

Gastric pH as a Possible Determinant of Anthocyanin Absorption

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01122160
Enrollment
13
Registered
2010-05-13
Start date
2010-05-31
Completion date
2010-12-31
Last updated
2013-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anthocyanin Metabolism

Keywords

anthocyanin, omeprazole, Prilosec, gastric pH, proton pump inhibitor, PPI, nutrition

Brief summary

Anthocyanins are phytonutrients that provide blue, purple and red colors to fruits and vegetables. The purpose of the study is to determine whether absorption of anthocyanins occurs in the acid pH of the stomach and to determine whether altering stomach pH by use of an over-the-counter medicine, Prilosec TM, alters absorption of anthocyanins from strawberries and blackberries.

Interventions

DRUGomeprazole

omeprazole 20.6 mg tablet with berries (blackberries + strawberries)

DRUGplacebo

Placebo with berries (blackberries + strawberries)

Sponsors

USDA Beltsville Human Nutrition Research Center
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
22 Years to 59 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI 18.5 kg/m2 to 30 kg/m2 * Age 22 to 59 years

Exclusion criteria

* Plans to have MRI analysis or other contact with MRI equipment during the study * Has implanted or portable electro-mechanical medical device such as a cardiac pacemaker or infusion pump * Suspected strictures, fistulas or physiological GI obstruction * Allergy to omeprazole * Current use of clopidogrel (Plavix) or use within the past 3 months * Use of warfarin, prescription antifungals/anti-yeast drugs, diazepam, and digoxin * Chronic daily use of nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, etc.) * History of bariatric or other gastric surgery * Frequent use of antacids * Use of proton pump inhibitors in past 3 months * History of acid reflux * History of gastrointestinal disorders or gastrointestinal surgery * History of bezoars (packed collection of partially digested or undigested material that is unable to exit the stomach) * Crohn's disease, diverticulitis or inflammatory bowel disease * Inability to swallow large pills * Dysphagia (Trouble or pain with swallowing food or pills) * Allergy to strawberries or blackberries * Pregnant women * Lactating women * Pregnancy in last 12 months * History of kidney disease * History of liver disease * History of metabolic disorder * History of some cancers * Tobacco use in past 6 months * Use of oral or IV antibiotics in past month * Use of herbal supplement in past month

Design outcomes

Primary

MeasureTime frame
Gastric pH1 hour prior to gastric emptying on Day 7 of the given intervention

Countries

United States

Participant flow

Pre-assignment details

Discrepancy between actual enrollment and number of participants in participant flow module is due to enrolled participants no longer meeting exclusion criteria (i.e., inability to swallow capsule).

Participants by arm

ArmCount
All Study Participants
All participants received both interventions.
11
Total11

Baseline characteristics

CharacteristicAll Study Participants
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
11 Participants
Age Continuous35 years
STANDARD_DEVIATION 13.8
Region of Enrollment
United States
11 participants
Sex: Female, Male
Female
4 Participants
Sex: Female, Male
Male
7 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 110 / 11
serious
Total, serious adverse events
0 / 110 / 11

Outcome results

Primary

Gastric pH

Time frame: 1 hour prior to gastric emptying on Day 7 of the given intervention

ArmMeasureValue (MEAN)Dispersion
ExperimentalGastric pH0.96 pHStandard Deviation 0.37
PlaceboGastric pH2.31 pHStandard Deviation 0.63

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026